Hot Biotech Gainers: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), XOMA Corporation (NASDAQ:XOMA), Sarepta Therapeutics (NASDAQ:SRPT), Synthetic Biologics Inc. (NYSEMKT:SYN), Sunesis Pharmaceuticals (NASDAQ:SNSS)


ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), announced the marketing approval of IclusigTM (ponatinib) in Australia by the Therapeutic Goods Administration (TGA). Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) in last trading activity advanced 9.66% to close at $7.15. Company weekly performance is 18.38% while its quarterly performance stands at 10.00%. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is -27.26% away from its 52 week high.

XOMA Corporation (NASDAQ:XOMA) on Nov. 6 reported a loss of $14.4 million in its third quarter. On a per-share basis, the company said it had a loss of 17 cents. Losses, adjusted for non-recurring gains, came to 20 cents per share. The results missed Wall Street expectations. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 18 cents per share. The drug developer posted revenue of $5.1 million in the period, which also fell short of Street forecasts. Analysts expected $5.4 million, according to Zacks. On last trading day XOMA Corporation (NASDAQ:XOMA) advanced 14.81% to close at $5.27. Its volatility for the week is 8.10% while volatility for the month is 6.10%. XOMA’s sales growth for past 5 years was -12.20% and its EPS growth for past 5 years was 22.50%. XOMA Corporation (NASDAQ:XOMA) monthly performance is 22.56%.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) recently announced a new study to confirm the dosages of their lead drug eteplirsen as a new therapeutic for treating Duchenne muscular dystrophy-affected patients with a baseline 6-minute walk test score. On last trading day Sarepta Therapeutics, Inc. (NASDAQ:SRPT) advanced 5.59% to close at $16.61. Its volatility for the week is 4.55% while volatility for the month is 6.16%. SRPT’s sales growth for past 5 years was -7.80% and its EPS growth for past 5 years was -9.80%. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) monthly performance is -29.50%.

Synthetic Biologics, Inc. (NYSE:SYN) announced that its Investigational New Drug (IND) application which was submitted to the U.S. Food and Drug Administration (FDA) in October will be proceeding into clinical trials for the development of the Company’s oral beta-lactamase enzyme SYN-004 for the prevention of Clostridium difficile (C. difficile) infection (CDI), antibiotic-associated diarrhea (AAD) and secondary infections with healthcare-acquired, drug-resistant pathogens in patients receiving intravenous (IV) beta-lactam antibiotic therapy. Synthetic Biologics plans to begin Phase 1a and 1b clinical trials shortly, with topline data expected to be reported before year-end.Synthetic Biologics Inc. (NYSEMKT:SYN) has 3.79% insider ownership while its institutional ownership stands at 26.90%. In last trading activity company’s stock closed at $1.69.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) on 19November announced the online publication of results from the Company’s Phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia (AML) in the November 7, 2014 Ahead of Print issue of Haematologica. On Monday shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) closed at $2.26. Company’s sales growth for last 5 years was 8.20%.


Leave a Reply

Your email address will not be published. Required fields are marked *